The Technical Analyst
SQZ Biotechnologies [SQZ]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
SQZ Biotechnologies Price, Forecast, Insider, Ratings, Fundamentals & Signals
61.11% $0.435
America/New_York / 3 jul 2023 @ 13:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 12.83 mill |
| EPS: | -2.16 |
| P/E: | -0.201 |
| Earnings Date: | Aug 02, 2023 |
| SharesOutstanding: | 29.49 mill |
| Avg Daily Volume: | 0.554 mill |
| RATING 2023-09-01 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.201 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.201 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0158 - 0.0858 ( +/- 68.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-14 | Vink Patrick V.j.j. | Buy | 39 875 | Stock Option |
| 2023-06-14 | Srivastava Sapna | Buy | 39 875 | Stock Option |
| 2023-06-14 | Schulman Amy W | Buy | 39 875 | Stock Option |
| 2023-06-14 | Schegerin Marc | Buy | 39 875 | Common Stock |
| 2023-06-14 | Jensen Klavs F. | Buy | 39 875 | Stock Option |
| INSIDER POWER |
|---|
| 99.95 |
| Last 97 transactions |
| Buy: 14 673 100 | Sell: 2 196 730 |
Forecast:
01:40 - $-0.0080
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.435 (61.11% ) |
| Volume | 30.14 mill |
| Avg. Vol. | 0.554 mill |
| % of Avg. Vol | 5 444.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SQZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SQZ
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest Press Releases
2023-07-03 13:30:00 - Press Release
Nyse To Commence Delisting Proceedings Against Sqz Biotechnologies Company (sqz)
New york--(business wire)--the new york stock exchange (“nyse”, the “exchange”) announced today that the staff of nyse regulation has determined to commence proceedings to delist the common stock of sqz biotechnologies company (the “company”) — ticker symbol sqz — from the nyse. trading in the company's common stock will be suspended immediately. nyse regulation reached its decision to delist the company's common stock pursuant to section 802.01b of the nyse's listed company manual because the.
2022-09-07 16:30:00 - Press Release
Sqz Biotechnologies To Present At Upcoming Investor Conferences
Watertown, mass.--(business wire)--sqz biotechnologies company (nyse: sqz), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that armon sharei, ph.d., chief executive officer and founder at sqz biotechnologies, will present at the h.c. wainwright 24th annual global investment conference on september 14 and at the chardan 6th annual genetic medicines conference on october 4. both conference presentations will be held in new york, ny. prese
2022-06-01 16:45:00 - Press Release
Sqz Biotechnologies To Present At Jefferies Healthcare Conference
Watertown, mass.--(business wire)--sqz biotechnologies (nyse: sqz), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that armon sharei, ph.d., chief executive officer and founder of sqz biotechnologies, will present at the jefferies healthcare conference on june 8, in new york, ny. presentation time and webcast information is available below. presentation details wednesday, june 8 jefferies healthcare conference 2:30-2:55 p.m. et webcast
2022-04-06 16:45:00 - Press Release
Sqz Biotechnologies To Present At Upcoming Investor Conferences
Watertown, mass.--(business wire)--sqz biotechnologies (nyse: sqz), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that armon sharei, ph.d., chief executive officer and founder of sqz biotechnologies, will present at the 21st annual needham virtual healthcare conference on april 13, and chardan's 6th annual genetic medicines & cell therapy manufacturing summit on april 26. presentation times and webcast information are available bel
2022-03-08 16:45:00 - Press Release
Sqz Biotechnologies To Present New Enhanced Apc Platform Preclinical Findings And Envoy-001 Phase 1/2 Clinical Trial In Progress Poster At The American Association For Cancer Research 2022 Annual Meeting
Watertown, mass.--(business wire)--sqz biotechnologies company (nyse: sqz), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company's enhanced antigen presenting cell (eapc) platform at the american association for cancer research (aacr) annual meeting on april 8-13, 2022 in new orleans, louisiana. the new eapc work demonstrates the company's cell squeeze® platform's ability to deliver
Latest News
2023-05-10 20:31:08 - Zacks Investment Research
SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates
SQZ Biotechnologies Company (SQZ) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.75 per share a year ago.
2022-09-07 16:30:00 - Business Wire
SQZ Biotechnologies to Present at Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 and at the Chardan 6th Annual Genetic Medicines Conference on October 4. Both conference presentations will be held in New York, NY. Prese
2022-06-08 14:30:05 - Seeking Alpha
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.
2022-06-01 16:45:00 - Business Wire
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Jefferies Healthcare Conference on June 8, in New York, NY. Presentation time and webcast information is available below. PRESENTATION DETAILS Wednesday, June 8 Jefferies Healthcare Conference 2:30-2:55 p.m. ET Webcast
2022-04-06 16:45:00 - Business Wire
SQZ Biotechnologies to Present at Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, and Chardan's 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26. Presentation times and webcast information are available bel
2022-03-08 16:45:00 - Business Wire
SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company's enhanced antigen presenting cell (eAPC) platform at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022 in New Orleans, Louisiana. The new eAPC work demonstrates the company's Cell Squeeze® platform's ability to deliver
2021-12-02 13:31:29 - Benzinga
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Human Papillomavirus positive (HPV16+) solid tumors. The investigational cell therapy is being evaluated in certain patients with advanced or metastatic HPV16+ cancers.
2021-11-29 16:45:00 - Business Wire
SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4th Annual Evercore ISI HealthCONx Conference on December 1st. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings. PRESENTATION DETAILS Wednesday, December 1 4th Annual Evercore ISI HealthCONx Conferenc
2021-11-15 16:45:00 - Business Wire
SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Stifel 2021 Virtual Healthcare Conference on November 17. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings. PRESENTATION DETAILS Wednesday, November 17 Stifel 2021 Virtual Healthcare Conference 10:00 a
2021-10-04 06:45:00 - Business Wire
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates across three oncology programs at various stages of development. The data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually. “We are excited to share new preclinical data on our AAC a